Company intelligence / Profile preview

Nexcelom Bioscience

Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Nexcelom Bioscience was a biotechnology tools company that developed and marketed image cytometry products for automated cell counting and analysis. The company was acquired by Revvity, and its product portfolio including Cellometer automated cell counters, Cellaca high-throughput systems, and Celigo image cytometers are now part of Revvity's offerings. The acquisition was valued at $260 million. The company's technology served the life science research, drug discovery, and pharmaceutical development sectors, with applications in cell therapy, bioprocessing, and clinical research.

Industry: Pathology

Partnerships

De Novo Software

Beyond the preview

Go deeper on Nexcelom Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nexcelom Bioscience.

Explore the full profile